Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

BACKGROUND: In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G, Niewerth, Denise, van Meerloo, Johan, Cloos, Jacqueline, van der Veer, Michael, Scheffer, George L, Peters, Godefridus J, Chan, Elena T, Anderl, Janet L, Kirk, Christopher J, Zweegman, Sonja, Dijkmans, Ben AC, Lems, Willem F, Scheper, Rik J, de Gruijl, Tanja D, Jansen, Gerrit
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2013
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3560160/
https://ncbi.nlm.nih.gov/pubmed/23305345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-2-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak